Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23
Erlotinib therapy in advanced non small-cell lung cancer
Abstract
Erlotinib is one of epithelial growth factor receptor tyrosine kinase inhibitors. Treatment of selected patient groups may result in prolonged survival time and improved quality of life during therapy. Patients who benefit most from this therapy are those with confirmed activating mutations within the EGFR gene, in good general condition. These drugs are well tolerated and do not require hospitalization, which is very important for the patients and their families We present the case of a male with advanced non small cell lung cancer who receives erlotinib.
Keywords: erlotinibnon small cell lung cancerEGFRtarget therapy